A carregar...
Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease
Overactivation of Src has been linked to the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD). This phase 2, multisite study assessed the efficacy and safety of bosutinib, an oral dual Src/Bcr-Abl tyrosine kinase inhibitor, in patients with ADPKD. Patients with ADPKD, eGFR≥60 ml/...
Na minha lista:
| Publicado no: | J Am Soc Nephrol |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Nephrology
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5661280/ https://ncbi.nlm.nih.gov/pubmed/28838955 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2016111232 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|